Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?

Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain (KD) mutation testing have a well consolidated role in the routine management of chronic myeloid leukemia (CML) patients, as they provide precious information for therapeutic decision-making. Molecular response levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Soverini, Simona, Bernardi, Simona, Galimberti, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760306/
https://www.ncbi.nlm.nih.gov/pubmed/33261150
http://dx.doi.org/10.3390/jcm9123865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760306/
https://www.ncbi.nlm.nih.gov/pubmed/33261150
http://dx.doi.org/10.3390/jcm9123865

Ejemplares similares